About the Company
We do not have any company description for Coherus Oncology, Inc. at the moment.
Exchange
Nasdaq
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest News on Coherus Oncology, Inc.
Coherus Oncology, Inc. (NASDAQ:CHRS) is largely controlled by institutional shareholders who own 54% of the company
If you want to know who really controls Coherus Oncology, Inc. (NASDAQ:CHRS), then you'll have to look at the makeup of its share registry. We can see that institutions own the lion's share in the ...
Coherus Oncology Inc (CHRS) Q2 2025 Earnings Call Highlights: Strong Revenue Growth and ...
Coherus Oncology Inc (CHRS) reports a 36% revenue increase and outlines strategic initiatives to bolster its oncology ...
Coherus Oncology, Inc. (NASDAQ:CHRS) is largely controlled by ...
We note that hedge funds don't have a meaningful investment in Coherus Oncology. The company's largest shareholder is The Vanguard Group, Inc., with ownership of 9.6%. With 9.5% and 4.5% of the shares ...
Need To Know: Analysts Are Much More Bullish On Coherus Oncology, Inc. (NASDAQ:CHRS) Revenues
Coherus Oncology, Inc. (NASDAQ:CHRS) shareholders will have a reason to smile today, with the analysts making substantial upgrades to this year's forecasts. The consensus estimated revenue numbers ...
Coherus Oncology Reports Second Quarter 2025 Financial Results and ...
REDWOOD CITY, Calif., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (Nasdaq: CHRS), today reported financial results for the second quarter ended June 30, 2025 and provided an overview ...
Coherus To Acquire Surface Oncology; Surface To Slash 50% ... - Nasdaq
(RTTNews) - Coherus BioSciences, Inc. (CHRS), announced on Friday that it has entered into a definitive merger agreement to acquire Surface Oncology Inc. (SURF).
Coherus Oncology, Inc.: Coherus Completes Strategic Transformation to ...
COHERUS ONCOLOGY INC WKN: A12ETZ | ISIN: US19249H1032 | Ticker-Symbol: 8C5 Tradegate 24.06.25 | 17:10 ...
Coherus Oncology, Inc. (CHRS) - Yahoo Finance
Coherus to Present Data from a Phase 1 Dose Expansion Study of CHS-114, a Cytolytic Antibody Targeting Chemokine Receptor 8 (CCR8), at the 2025 American Association for Cancer Research (AACR) Annual ...
2023-09-08 | NDAQ:CHRS | Press Release | Coherus BioSciences Inc
REDWOOD CITY, Calif., Sept. 08, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Coherus, Nasdaq: CHRS) today announced the closing of the previously announced acquisition of Surface Oncology, Inc.
Coherus Oncology Analyst Ratings and Price Targets | NASDAQ:CHRS | Benzinga
Coherus Oncology Inc has a consensus price target of $9.01 based on the ratings of 9 analysts. The high is $21 issued by Mizuho on November 16, 2022. The low is $1.05 issued by UBS on April 24, 2025.
Coherus BioSciences Acquires Small Immuno-Oncology Player Surface ...
$40.82 -0.92 % NVS Novartis AG $118.01 -0.01 % Coherus BioSciences Inc CHRS +1.83% Get Free Report has agreed to acquire Surface Oncology Inc ...
Coherus Completes Strategic Transformation to Coherus Oncology ... - Nasdaq
--Coherus Oncology, Inc., a commercial-stage innovative oncology company, formerly named Coherus BioSciences Inc., announced its name change today to better align with its exclusive focus on ...
Similar Companies
Loading the latest forecasts...